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Abstract
Attention-deficit/hyperactivity disorder (AD/HD) is a common pediatric behavioral disorder associated, in part, with 
male preponderance and reduced regional cerebral blood flow (rCBF). However, mechanism(s) underlying male 
preponderance and reduced rCBF in AD/HD are unclear. The present study profiles the expression of angiogenic and 
hormonal factors likely to underlie these symptoms using a recently characterized AD/HD animal model, juvenile male 
stroke-prone spontaneously hypertensive rats (SHRSP). Because vascular endothelial growth factor (VEGF) signaling 
cascade and gonadal steroids are key regulators of angiogenesis and gender based behavior, respectively, we profiled 
their patterns of expression in the frontal cortex of SHRSP to elucidate their roles in the genesis of AD/HD male 
preponderance and rCBF. Interestingly, levels of VEGF, VEGF receptors (KDR, Flt-1), endothelial nitric oxide synthase, 
phosphorylated Akt (pAkt), estrogen receptor-B, aromatase, and capillary density in sham-operated SHRSP were 
remarkably down-regulated, whereas androgen receptor levels were up-regulated, compared with age-matched genetic 
control, Wistar-Kyoto rats. Castration, estrogen, and androgen receptor antagonist (flutamide) counteracted these 
effects. Dihydrotestosterone, but not testosterone, reversed the beneficiary effects of castration. Estrogen receptor-B 
levels remained unchanged in all groups examined. We postulate that changes in androgen metabolism that tend to up-
regulate local dihydrotestosterone concentration and diminish estrogen synthesis, in the frontal cortex of juvenile male 
SHRSP, may lower levels and/or activity of VEGF and its signaling cascade and, subsequently, reduce rCBF. These 
findings could, in part, help explain the pathogenesis of reduced rCBF and male preponderance in AD/HD. 
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A TTENTION-DEFICIT/HYPERACTIVITY  DISORDER (AD/HD) is a common pediatric behavioral disorder 
characterized by inattention, hyperactivity, and impulsivity 
that can lead to social, affective, and learning impairments at 
school (1, 2). Because boys are 6 –9 times more prone to be 
diagnosed with AD/HD (3, 4) and because volumetric ab- 
normalities in regional cerebral blood flow (rCBF) in some 
brain regions, including the frontal cortex and striatum, are 
common in AD/HD (2, 5–11), key factors likely to play im- 
portant roles in AD/HD pathogenesis include gender- and 
vascular-associated factors. 
The precise factors that underlie male preponderance in 
AD/HD have not been fully elucidated. The possible in- 
volvement of gonadal hormones in AD/HD male prepon- 
Abbreviations: AD/HD, Attention-deficit/hyperactivity disorder; 
AR, androgen receptor; aromatase, aromatase P450; CNS, central ner- 
vous system; DHT, dihydrotestosterone; E, 17[3-estradiol; eNOS, endo- 
thelial NO synthase; ER, estrogen receptor; ERKO, ER knockout; GSA- 
B4, Griffonia simplicifolia; NO, nitric oxide; pAkt, phosphorylated Akt; 
PVDF, polyvinylidene diflouride filter; rCBF, regional cerebral blood 
flow; SHR, spontaneously hypertensive rat; SHRSP, stroke-prone SHR; 
TPBS, PBS containing 0.1% Tween 20; Ts, testosterone; VEGF, vascular 
endothelial growth factor; WKY, Wistar-Kyoto rat. 
derance is based on their critical role in shaping develop- 
mentally programmed sex differences in the forebrain (12, 
13) and their involvement in several psychopathologies (14).
Importantly, a growing body of evidence indicates involve- 
ment of gonadal hormones and their receptors in the patho- 
genesis and clinical symptom manifestations in AD/HD sub- 
jects, although conclusive mechanistic insights and 
explanations are yet to be clarified (15–20). Gonadal hor- 
mones influence key projecting neurons, including dopami- 
nergic and cholinergic systems that play a major role in rCBF 
and whose regulation is disrupted in AD/HD (3, 15, 16, 
21–33). Indeed, dopaminergic or cholinergic interventions 
restore rCBF and cerebral dysfunction in AD/HD patients 
(23, 34) and animal models (35, 36). Alternatively, gonadal 
hormones are, in addition, likely to directly influence rCBF 
by modulating factors that regulate vascular development 
and function, such as vascular endothelial growth factor 
(VEGF) (37– 40). VEGF is widely distributed in multiple cell 
types of the central nervous system (CNS) and is known to 
exert a trophic effect on endothelial, neuronal, and glial cells, 
an essential process during CNS development and repair 
(41). VEGF optimal concentration in the CNS is critical and, 
for this reason, tightly regulated to maintain optimal activity 
(42). Intermediate or suboptimal VEGF levels lead to de- 
creased blood vessel branching and density in the cerebral 
cortex (42), and severe reductions of VEGF are fatal, leading 
to hypoxia and, subsequently, degeneration of cerebral cor- 
tex and neonatal lethality (42). Collectively, these observa- 
tions strongly support the hypothesis that alterations of 
VEGF concentration orchestrated by changes in gonadal hor- 
mone synthesis and/or metabolism, at a critical time of fron- 
tal cortex development, could compromise rCBF. These 
changes may predispose the animal to AD/HD. 
Several animals have been proposed as models of AD/HD 
(43– 45). However, very few sufficiently exhibit the symp- 
tomatic and therapeutic profiles seen in AD/HD patients. 
For instance, in the most commonly used model, spontane- 
ously hypertensive rats (SHRs), male preponderance is not 
observed, whereas female, but not male, SHRs exhibit im- 
pulsivity-inattention, although both are hyperactive (46). 
Furthermore, the effectiveness of psychostimulants in SHRs 
is not consistent with the behavioral paradigms used (47). We 
recently established juvenile stroke-prone SHRs (SHRSPs), a 
substrain of SHR, as a new animal model for AD/HD (35, 36). 
Interestingly, this animal model, apparently, exhibits all the 
key behavioral symptoms seen in human AD/HD subjects, 
including hyperactive, impulsive-like behavior, and/or in- 
attention (35). Furthermore, similar to human AD/HD sub- 
jects, SHRSPs exerted male preponderant impairment in at- 
tentional performance, which was normalized by clinical 
dosages of methylphenidate (35). Neurochemical and cog- 
nitive studies of male SHRSPs revealed dopaminergic hy- 
pofunction in the prefrontal cortex, nucleus accumbens shell, 
striatum, and basolateral amygdala (48) as well as cognitive 
impairment, accompanied by central cholinergic dysfunction 
(49). Moreover, the SHRSP displays higher motor activity 
than the SHR (50), and cerebrospinal fluid serotonin levels 
are significantly decreased in the SHRSP, but not in the SHR, 
as compared with genetic control Wistar-Kyoto rats (WKYs) 
(51). 
More recently, we found that gonadal hormone manipu- 
lations altered the behavior of juvenile male SHRSPs (52). 
Male SHRSPs exhibited an impairment in spontaneous al- 
ternation performance in a Y-maze, compared with the ge- 
netic control, WKYs, which was ameliorated by gonadec- 
tomy (castration for 21 d) (52) but counteracted by 
replacement of the nonaromatizable androgen, dihydrotes- 
tosterone (DHT) (for 3 wk at 250 µg/kg, daily) (52). Sur- 
prisingly, the aromatizable androgen, testosterone (300 µg/ 
kg, daily), antiandrogen (flutamide) (10 mg/kg, daily, 21 d) 
or 17[3-estradiol (E; 10 µg/kg, daily, 21 d), unlike DHT, did 
not reverse the effects of gonadectomy on spontaneous al- 
ternation performance in SHRSPs (52). These findings sug- 
gest that alterations in gonadal hormone levels or metabo- 
lism may be one of the factors that underlie short-term 
memory deficit in male juvenile SHRSPs, an animal model of 
AD/HD (52). 
Thus, in the present study, we used juvenile (6 wk old) 
male SHRSPs to elucidate factors likely to underlie male 
preponderance and volumetric abnormalities in the frontal 
cortex of SHRSPs by examining the expression profiles of: 1) 
VEGF and basic VEGF signaling machinery [VEGF receptors 
(KDR and Flt-1), phosphorylated Akt (pAkt), and endothelial 
nitric oxide (NO) synthase (eNOS)]; 2) plasma gonadal ste- 
roid hormones [estrogen, testosterone (Ts), DHT]; 3) gonadal 
steroid hormone receptors [estrogen receptor (ER), androgen 
receptor (AR)]; and 4) aromatase P450 (aromatase). Further- 
more, the effects of castration and exogenous gonadal steroid 
hormones on the expression of the above molecules in 
SHRSP were investigated. 
 
Materials and Methods 
Animal Models 
Juvenile male SHRSPs (6 wk of age), inbred in our laboratory (current 
generation, F57), and a gender- and age-matched genetic control, WKYs 
(n = 20), were used in this study. All animals were kept under standard 
laboratory conditions (temperature of 22 ± 2 C and 12-h light, 12-h dark 
cycle). Forty SHRSPs, castrated at 3 wk of age, were divided into three 
groups treated sc (dorsally, on the neck) daily for 21 d with: 1) 10% 
ethanol in sesame oil (vehicle) (5 ml/kg, n = 14); 2) Ts (300 µg/kg, n = 
14); or 3) DHT (250 µg/kg, n = 12). In addition, 44 sham-operated 
3-wk-old SHRSPs were divided into three groups treated daily for 21 d 
with: 1) 10% ethanol in sesame oil, vehicle (5 ml/kg, n = 20), 2) E (10 
µg/kg, n = 12); or 3) flutamide, an AR blocker (10 mg/kg, n = 12) 
administered sc (dorsally, on the neck). Four to six hours after the last 
injection, animals were anesthetized with ketamine chloride (50 mg/kg, 
ip) (decapitation was not done), blood samples were collected via ab- 
dominal aortic puncture, and then brain tissues were harvested and 
either snap frozen in liquid nitrogen and preserved at -80 C (for cryostat 
sections, Western blot analysis or real-time PCR) or postfixed in 4% 
paraformaldehyde overnight (for paraffin sections). In another set of 
experiments, WKYs, which served as genetic control for SHRSPs, were 
also castrated (n = 6) at 3 wk of age and then killed after 3 wk for tissue 
harvest, as described above. All experimental procedures were ap- 
proved and performed in accordance with Hokkaido University School 
of Medicine Animal Care and Use Committee. 
Determination of plasma levels of E, Ts, and DHT 
Plasma levels of E, Ts, and DHT were determined by enzyme im- 
munoassay using the following kits: 1) rodent estradiol ELISA test kit 
(Endocrine Technologies, Inc., Newark, CA), 2) estradiol EIA kit (Cay- 
man Chemical, Ann Arbor, MI), 3) Ts ELISA (Immuno-Biological Lab- 
oratories, Hamburg, Germany), 4) Ts EIA kit (Cayman Chemical), 5) 
rodent Ts ELISA test kit (Endocrine Technologies), and 6) DHT ELISA 
(Immuno-Biological Laboratories). 
Comparable results were found for E and Ts from the kits mentioned 
above. The data presented in this manuscript for E and Ts were obtained 
using the kits of rodent estradiol ELISA test kit (Endocrine Technologies) 
and Ts ELISA (Immuno-Biological Laboratories), respectively. 
 
Immunolabeling 
Immunolabeling studies were undertaken to determine the expres- 
sion patterns of VEGF, Flt-1, KDR, eNOS, ERa, ER[3, AR, and aromatase 
expression in the frontal cortex of SHRSPs and WKYs. The specificities 
of these antibodies have been well characterized in our previous reports 
(53–57). 
Eight 10-µm-thick frozen coronal cryostat (VEGF, Flt-1, KDR, eNOS, 
aromatase) and 5-µm-thick paraffin (AR, ERa and -[3, aromatase) sec- 
tions of frontal cortex cut serially were immunolabeled as previously 
described (53–57). The paraffin sections were deparaffinized and treated 
for 20 min with citrate buffer [10 mm citric acid (pH 6.0)] in a microwave 
oven (750 W) before immunostaining. To prevent nonspecific staining, 
the cryostat and paraffin sections were blocked with nonimmune serum 
(1% BSA in Tris). The sections were then incubated overnight at 4 C with 
primary antibodies, rinsed in phosphate buffer solution and then ex- 
posed to the fluorescence secondary antibody, Cy3-conjugated Affi- 
niPure goat antirabbit IgG or fluorescein-conjugated AffiniPure goat 
antirabbit, antigoat and antimouse IgG (Jackson ImmunoResearch Lab- 
oratories, West Grove, PA), for 2 h, according to the manufacturer’s 
instructions. Sections processed without primary antibodies served as 
negative controls. The coverslips were mounted with Immunon 
(Thermo Shandon, Pittsburgh, PA). Immunofluorescent images were 
viewed using the laser scanning confocal imaging system (model MRC- 
1024; Bio-Rad Laboratories, Maryland, UK). The following antibodies, 
which are commercially available, were used: rabbit antihuman VEGF 
polyclonal antibody (Immunological Laboratories, Fujioka, Japan), rab- 
bit antihuman KDR polyclonal antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA), rabbit antihuman Flt-1 polyclonal antibody (Santa 
Cruz Biotechnology), rabbit antihuman eNOS polyclonal antibody (Af- 
finity BioReagents, Golden, CO), mouse ERa monoclonal antibody (No- 
vocastra Laboratories, Newcastle upon Tyne, UK), rabbit antihuman 
ER[3 polyclonal antibody (Affinity BioReagents), rabbit antihuman AR 
polyclonal antibody (Chemicon International, Temecula, CA), and rabbit 
antihuman aromatase polyclonal antibody (Santa Cruz Biotechnology). 
Western blot analysis 
After removing and rinsing the frontocortical tissues in sterilized PBS 
on ice, the tissues were minced with scissors, homogenized, and cen- 
trifuged at 500 X g for 15 min to pellet any insoluble material. The protein 
concentration of supernatant was determined using the bicinchoninic 
acid protein assay (Pierce, Rockford, IL). Samples were run on SDS- 
PAGE, using 7.5–15% polyacrylamide gel, and electrotransferred to 
polyvinylidene diflouride filter (PVDF) membrane. To reduce nonspe- 
cific binding, the PVDF membrane was blocked for 2  h at room tem- 
perature with 5% nonfat milk in PBS containing 0.1% Tween 20 (TPBS). 
Thereafter, the PVDF membrane was incubated overnight at 4 C with 
specific antibodies for VEGF, KDR, Flt-1, eNOS, pAkt (Ser 473) antibody 
(Cell Signaling Technology, Beverly, MA), ERa, ER[3, AR, and aromatase 
in TPBS; washed thrice in TPBS; and then (PVDF) incubated with horse- 
radish peroxidase-conjugated antirabbit (Amersham, Buckinghamshire, 
UK), antimouse (Amersham), or antigoat antibody (Santa Cruz Biotech- 
nology) diluted at 1:2,000 –10,000 in TPBS at room temperature for 60 
min. The blots were visualized with the enhanced chemiluminescence 
detection system (Amersham), exposed to x-ray film, and analyzed 
using free NIH image software. 
Immunoassay of VEGF and pAkt 
VEGF levels in rat frontocortical tissue (n = 8/group) were measured 
using a commercially available kit (VEGF immunoassay, R&D Systems, 
Minneapolis, MN), according to the manufacturer’s instructions. 
The level of Akt protein, phosphorylated at serine residue 473, in 
frontocortical tissue extract was quantitatively determined by ELISA kit, 
Akt (pS473) (BioSource International, Inc., Camarillo, CA). 
NO colorimetric assay 
NO was indirectly detected in brain tissue extracts as nitrite using a 
nitric oxide colorimetric assay kit (Roche Diagnostics GmbH, Mann- 
heim, Germany). In this method, the nitrate present in the sample was 
reduced to nitrite by reduced nicotinamide adenine dinucleotide phos- 
phate in the presence of the enzyme nitrate reductase. The nitrite formed 
reacted with sulfanilamide and N-(1-naphthyl)-ethylenediamine dihy- 
drochloride to give a red-violet diazo dye. The diazo dye was measured 
at 550 nm, on the basis of its absorbance within the visible range. 
In situ hybridization 
Twenty-micrometer-thick serial frozen coronal sections of frontal cor- 
tex were prepared and mounted on glass slides precoated with 3-amino- 
propyltriethoxysilane. The sections were then fixed by 4% paraformal- 
dehyde with 0.25% acetic anhydride in 0.1 m triethanolamine-HCl (pH 
8.0). The hybridization procedure was performed as previously de- 
scribed (53–58). The specificities of the probes used in the present in- 
vestigation have already been well characterized in our previous reports 
(53–58). The probes were complementary to nucleotide residues 61–106 
of VEGF cDNA (accession no. AF239170), 541–585 of KDR cDNA (ac- 
cession no. U93306), 961-1016 of Flt-1 cDNA (accession no. D28498), 
841– 885 of eNOS cDNA (accession no. X76309), 301–346 of ERa cDNA 
(accession no. Y00102), 45–90 of ER[3 cDNA (accession no. U57439), and 
1621–1666 of AR cDNA (accession no. NM012502). Specific 60-bp-long 
oligonucleotides of the rat cytochrome P450 aromatase cDNA used by 
Lauber and Lichtensteiger (59) were purchased. The oligonucleotides 
were labeled with 35S-dATP using terminal deoxyribonucleotidyl trans- 
ferase. The radiolabeled probes were hybridized to the tissue in a pre- 
hybridization buffer for 10 h at 42 C. The sections were either exposed 
to Hyperfilm-[3max (Amersham) for 4 wk or dipped in NTB2 nuclear 
track emulsion (Kodak, Rochester, NY) and exposed for 4 – 8 wk. The 
specificity of in situ hybridization was confirmed by the disappearance 
of signals when excess doses of the corresponding nonlabeled (35S- 
dATP) antisense oligonucleotides (cold) were added to the labeled an- 
tisense oligonucleotides (hot) hybridization fluid. Consistent mRNA 
signals for each molecule above background levels were considered 
positive and were scored, subjectively, as strong, moderate, or weak. 
 
RNA preparation and real-time quantitative PCR 
Protocol used for the real-time quantitative PCR in the present study 
has already been published in a previous report (56). Total RNA samples 
were prepared from frontocortical tissues by the guanidinium thiocy- 
anate-phenol-chloroform single-step extraction method with Isogen 
(Nippon Gene, Toyama, Japan) used routinely in our laboratory (56). 
After being isolated, treated with DNase I, and quantified, RNA was 
reverse transcribed to cDNA by the use of a ReverTra Ace (Toyobo, 
Osaka, Japan). 
The single-stranded cDNA was then used in real-time quantitative 
PCR for evaluation of relative expression levels of the eight genes of 
interest. Selected genes and primers are shown in Table 1. DNA am- 
plification was performed in the Applied Biosystems (ABI 7900HT) 
real-time PCR machine with the GeneAmp 7900HT sequence detection 
system software (PerkinElmer Corp., Foster City, CA), and the detection 
was made by measuring the binding of the fluorescence dye SYBR Green 
I to double-stranded DNA. The PCRs were set up in microtubes in a 
volume of 20 µl. The reaction components were 2 µl cDNA synthesized 
as above, 10 µl of 2X SYBR Green master mix (PerkinElmer Corp.), and 
0.4 µm of each pair of oligonucleotide primers (Table 1). The program 
was as follows: an initial step at 95 C for 10 min and then 40 cycles of 
95 C for 15 sec and 60 C for 60 sec. Regression curves were drawn for 
each sample, and its relative amount was calculated from the threshold 
cycles with the instrument’s software (SDS 2.0) according to the man- 
ufacturer’s instructions. The PCR products were analyzed by gel elec- 
trophoresis to confirm the specificity of generated products. Relative 
expression levels of the target genes were normalized to the geometric 
mean of the two internal control genes, [3-actin and glyceraldehyde-3- 
phosphate dehydrogenase. 
Capillary morphology 
Previous studies have shown that histochemical staining with the 
lectin Griffonia simplicifolia (GSA-B4) is a sensitive and reliable method 
TABLE 1. Primers and conditions for real-time quantitative PCR analyses 
Gene 
Sense 
Primers (5'–3')  
Antisense 
Product size (bp) 
VEGF GTACCTCCACCATGCCAAGT GCATTAGGGGCACACAGGAC 194 
KDR CAGAAAAGGAGATGCCCGAC TCCAGAGTTTTCAGCTCTTC 300 
Flt-1 AGGAGAGGACCTGGAACTGTCTT  ATTCCTGGGCTCTGCAGGCATAG 470 
eNOS CTGCTGCCCCAGATATCTTC CAGGTACTGCAGTCCCTCCT 230 
ERa CTTCTGGAGTGTGCCTGGTT CTTCTCCCTGCAGGTTCATC 199 
ER[3 CCTTGAAGGCTCTCGTGTTA TAGAAGACGCCATCCAAAGG 200 
AR CAACTTGCATGTGGATGACC TGAGAAAGGTGCCTCATCCT 198 
Aromatase CCTGGAGATGACGTGATTG CGATGTACTTCCCAGCACAG 197 
to visualize the capillary vasculature in the frontal cortex of rat brain (53). 
Eight-micrometer-thick serial frozen coronal sections of frontal cortex 
were stained with GSA-B4 (Sigma Chemical, St. Louis, MO). The sections 
were fixed with acetone, air dried, and placed in PBS. After being treated 
with 3% H2O2 in methanol and washed in PBS, the sections were in- 
cubated with GSA-B4 (1:100 dilution in PBS) overnight at 4 C, followed 
by reaction with streptoavidin conjugated to peroxidase (Nichirei Corp., 
Tokyo, Japan) and through rinse in PBS. For visualization diaminoben- 
zidine/H2O2 as chromogen was used. To enhance the diaminobenzidine 
reaction, the sections were rinsed with 0.05 m NaHCO3 (pH 9.6) and then 
incubated in diaminobenzidine enhancing solution (Vector Laborato- 
ries, Burlingame, CA). Vascular endothelium was stained with lectin, 
which stained capillaries as black/dark brown dots. Sections were ex- 
amined using a microscope (Olympus, Tokyo, Japan), and counts were 
made of stained capillaries in cross-sections in 30 fields (117,617 µm2/ 
field) per sample (section on slide) at a final magnification of X400 by 
an image-analyzing software (microcomputer imaging device, Imaging 
Research, St. Catharine, Ontario, Canada). This counting method has 
been well established by previous reports (53, 54, 57). Furthermore, the 
number of lectin-stained capillaries were quantified by two independent 
researchers in a double-blinded study. Care was taken to avoid counting 
the same single capillary twice. Any microvessel (defined as a vessel 
having internal diameter < 100 µm) that had no apparent lumen was 
considered as a single capillary. 
Capillary density was also assessed light-microscopically on 5-µm- 
thick deparaffinized tissue sections that were immunostained by anti- 
von Willebrand factor (FVIII) antibody (53) (Dako, Hamburg, Germany) 
or CD34 (Santa Cruz Biotechnology). The antibodies were made visible 
by a secondary exposure of the sections to Cy3-conjugated AffiniPure 
donkey antirabbit IgG (Jackson ImmunoResearch Laboratories). 
Statistical analysis 
Data are  expressed  as  the  mean ± sd. Homogeneity of  variance 
between groups was checked by Bartlett’s test. Data were compared 
using one-way ANOVA (ELISA data, basal data of immunoblot, cap- 
illary density). Post hoc comparisons were made with Scheffé’s multi- 
comparison test. A two-tailed Student’s t test was used to analyze 
differences between two group means (sham-operated WKY and cas- 
trated WKY). Differences were considered significant at P < 0.05. 
Results 
Plasma levels of Ts, DHT, and E 
Plasma levels of Ts (1.52 ± 1.30 ng/ml, n = 12) and DHT 
(0.24 ± 0.10 ng/ml, n = 12) in sham-operated SHRSPs were 
significantly (P < 0.01) higher than those of WKYs (Ts: 0.73 ± 
0.45 ng/ml, n = 12; DHT: 0.13 ± 0.07 ng/ml, n = 12). After 
castration, levels of Ts and DHT were markedly decreased in 
SHRSPs: Ts (0.20 ± 0.18 ng/ml, n = 10) and DHT (0.03 ± 0.01 
ng/ml, n = 10) (P < 0.01). 
Replacement with Ts (300 µg/kg·d) for 21 d restored 
plasma levels of Ts in castrated SHRSPs (1.44 ± 0.78 ng/ml, 
n = 10) identical to that in sham-operated SHRSPs. DHT 
plasma levels decreased to 0.10 ± 0.05 ng/ml (n = 10) after 
Ts replacement in castrated SHRSPs, compared with sham- 
operated SHRSPs. 
Replacement with DHT (250 µg/kg·d) for 21 d restored 
plasma levels of DHT (0.22 ± 0.10 ng/ml) in castrated SHR- 
SPs to those observed in sham-operated SHRSPs. However, 
plasma Ts levels remained unchanged after DHT replace- 
ment in castrated SHRSPs (0.3 ± 0.01 ng/ml), compared with 
vehicle-treated castrated SHRSPs. 
Treatment of sham-operated SHRSPs with E (10 µg/kg·d), 
on the contrary, markedly decreased (P < 0.01) plasma levels 
of both Ts (0.24 ± 0.05 ng/ml) (n = 10) and DHT [below 
detectable levels (<0.02 ng/ml, n = 10)], compared with 
sham-operated SHRSPs. 
Treatment of sham-operated SHRSPs with AR blocker, 
flutamide (10 mg/kg·d), also significantly (P < 0.01) de- 
creased plasma Ts (0.30 ± 0.29 ng/ml, n = 10) and DHT 
levels (0.09 ± 0.07 ng/ml, n = 10), compared with sham- 
operated SHRSPs. 
Plasma levels of E (12.01 ± 5.37 pg/ml, n = 16) were 
significantly (P < 0.01) lower in sham-operated SHRSPs than 
WKYs (22.45 ± 6.67 pg/ml, n = 16) and decreased further 
after the castration of SHRSPs (6.01 ± 4.03 pg/ml, n = 6) (P < 
0.01). Administration of E significantly increased plasma lev- 
els of E (70.02 ± 50.1 pg/ml, n = 8; P < 0.001) in sham- 
operated SHRSPs. Furthermore, Ts replacement in castrated 
SHRSPs changed plasma E levels to 25.0 ± 11.2 pg/ml (n = 
8), which was almost comparable with those in WKYs. 
 
Expression of VEGF and receptors (KDR, Flt-1) 
Strong immunofluorescent staining for VEGF and its re- 
ceptors (KDR and Flt-1) were localized in the microvessels of 
the frontal cortex from WKYs (Fig. 1). In contrast, in sham- 
operated SHRSPs, they were weakly stained but increased 
FIG. 1. Frontocortical serial sections from genetic control WKYs and 
SHRSPs [sham-operated (sham+vehicle), castrated SHRSPs 
(cast+vehicle), castrated SHRSPs replaced with Ts (cast+Ts), and 
castrated SHRSPs replaced with DHT (cast+DHT)] immunostained 
for VEGF, KDR, Flt-1, eNOS, ERa, ER[3, AR, and aromatase. Positive 
staining was shown in cerebral microvessels (internal diameter < 100 




after castration in SHRSPs (Fig. 1). Although Ts replacement 
had no effect on the levels of VEGF, KDR, and Flt-1 in cas- 
trated SHRSPs, DHT replacement down-regulated the cas- 
tration-induced expression of VEGF, KDR, and Flt-1 (Fig. 1). 
Using Western blot analysis, VEGF, KDR, and Flt-1 proteins 
in the rat frontocortical tissues extracts were detected as 
single bands migrating at 39, 200, and 180 kDa, respectively 
(Figs. 2, A and B, and 3A). Densitometric analysis for these 
bands revealed a significant (P < 0.001) reduction in relative 
protein levels of the frontocortical tissues from sham-oper- 
ated SHRSPs, compared with those of WKYs (Figs. 2, A and 
B, and 3A). Consistent with immunohistochemical data, 
VEGF, KDR, and Flt-1 protein levels were significantly in- 
creased after castration of SHRSPs, attenuated by DHT re- 
placement (Figs. 2, A and B, and 3A). Ts replacement exerted 
no effect on expression of these molecules in castrated SHR- 
SPs (Figs. 2, A and B, and 3A). When sham-operated SHRSPs 
were treated with E or flutamide, levels of VEGF, KDR, and 
Flt-1 were up-regulated (Figs. 2, A and B, and 3A). Fronto- 















FIG. 2. A and B, Immunoblot analysis for VEGF 
(A), and KDR (B) in the frontocortical tissues of 
genetic control WKYs (lane 1), sham-operated SHR- 
SPs (sham+vehicle) (lane 2), castrated SHRSPs 
[vehicle treated (cast+vehicle) (lane 3); Ts replaced 
(cast+Ts) (lane 4); DHT replaced (cast+DHT) (lane 
5)], sham-operated SHRSPs treated with E 
(sham+E) (lane 6), and sham-operated SHRSPs 
treated with flutamide (sham+flutamide) (lane 7). 
The panel of bands, just above the histogram, shows 
representative blots of the type of animal and/or 
treatment, as described above. The intensity of the 
bands were plotted as histograms, as shown below 
each panel. In each of the experiments, the band 
obtained with control WKYs is normalized as 1.0. 
Data are shown as means ± SD of five separate 
experiments. Statistical analysis was done for the 
basal data before normalization using one-way 
ANOVA followed by Scheffé’s multicomparison test. 
*, P < 0.001 vs. WKY; #, P < 0.001 vs. sham-oper- 
ated SHRSP; §, P < 0.001 vs. castrated SHRSP 
(vehicle). 
FIG. 3. A and B, Immunoblot analysis for Flt-1 (A) 
and eNOS (B) in the frontocortical tissues of ge- 
netic control WKYs (lane 1), sham-operated SHR- 
SPs (sham+vehicle) (lane 2), castrated SHRSPs 
[vehicle treated (cast+vehicle) (lane 3); Ts replaced 
(cast+Ts) (lane 4); DHT replaced (cast+DHT) 
(lane 5)], sham-operated SHRSPs treated with E 
(sham+E) (lane 6), and sham-operated SHRSPs 
treated with flutamide (sham+flutamide) (lane 7). 
The panel of bands, just above the histogram, 
shows representative blots of the type of animal 
and/or treatment, as described above. The inten- 
sity of the bands were plotted as histograms, as 
shown below each panel. In each of the experi- 
ments, the band obtained with control WKYs is 
normalized as 1.0. Data are shown as means ± SD 
of five to seven separate experiments. Statistical 
analysis was done for the raw data before normal- 
ization using one-way ANOVA followed by Schef- 
fé’s multicomparison test. *, P < 0.001 vs. WKY; #, 
P < 0.001 vs. sham-operated SHRSP; §, P < 0.001 
vs. castrated SHRSP (vehicle). 
significant (P < 0.01) decrease in sham-operated SHRSPs 
(16 ± 4 pg/mg), compared with WKYs (22 ± 3 pg/mg). 
However, after castration VEGF levels in SHRSPs were in- 
creased to 23 ± 4 pg/ml. Ts replacement maintained the 
increased VEGF levels in castrated SHRSPs (25 ± 4 pg/mg). 
DHT replacement in castrated SHRSPs decreased VEGF lev- 
els (13 ± 3 pg/mg) nearly to those observed in sham-oper- 
ated SHRSPs. 
Interestingly, contrary to the effects on SHRSPs, castration 
of WKYs resulted in a small (15 ± 6%) but significant (P = 
0.006) decrease in VEGF levels in the frontal cortex, com- 
pared with sham-operated WKYs, as revealed by ELISA. 
In situ hybridization (see Fig. 7) and real-time PCR (Table 
2) data corresponded to those of immunohistochemistry and
Western blot analysis described earlier: VEGF, KDR, and 
Flt-1 mRNA signals were: 1) reduced in the frontocortical 
tissues of sham-operated SHRSPs, compared with those in 
WKYs, and up-regulated after E or flutamide treatment; and 










Total RNA was extracted from the frontal cortex and subjected to real-time PCR quantification, as described in Materials and Methods. Values 
represent the amount of mRNA relative to that in WKY control rats, which is arbitrarily defined as 1. Sham-operated SHRSP (sham+vehicle), 
castrated SHRSP [vehicle treated- (cast+vehicle); testosterone replaced- (cast+Ts); dihydrotestosterone replaced- (cast+DHT)], sham-operated 
SHRSP treated with estrogen (sham+E), and sham-operated SHRSP treated with flutamide (sham+flutamide). 
2) increased after castration of SHRSPs and down-regulated
after DHT replacement in castrated SHRSPs. 
Expression of eNOS 
Both the distribution and expression patterns of eNOS 
mRNA and protein in the frontal cortex of sham-operated 
SHRSPs (vehicle, E, or flutamide), castrated SHRSPs (vehicle, 
Ts, or DHT), and genetic control WKYs matched those of 
VEGF above (Figs. 1, 3B, and 7; and Table 2). The predicted 
size of eNOS bands (~140 kDa) were detected in frontocor- 
tical tissues (Fig. 3B). 
Levels of NO (as nitrite) 
Frontocortical nitrite levels in sham-operated SHRSPs and 
control WKYs were 3.0 ± 0.5 and 4.2 ± 0.2 nmol/mg (P < 
0.01), respectively. Ts replacement in castrated SHRSPs 
raised the nitrite level to 5.1 ± 0.4 nmol/mg, but DHT re- 
placement strongly lowered the nitrite level in castrated 
SHRSPs to 2.7 ± 0.3 nmol/mg. E and flutamide treatments 
in sham-operated SHRSPs increased nitrite levels also to 
4.7 ± 0.4 and 4.4 ± 0.4 nmol/mg, respectively. 
Expression of pAkt 
Reduction of VEGF levels described above is expected to 
impact the expression of signaling molecule downstream of 
VEGF. Because Akt is an important downstream signaling 
molecule in VEGF-induced angiogenesis, we sought to de- 
termine whether there are changes in its expression in sham- 
operated SHRSPs and WKYs, as seen in VEGF. pAkt was 
clearly visualized as a major band with a molecular mass of 
55 kDa in rat frontocortical tissues using immunoblot anal- 
ysis (Fig. 4A). However, levels of pAkt in the frontal cortex 
of: 1) sham-operated SHRSPs treated with vehicle, E, or flu- 
tamide; 2) castrated SHRSP treated with vehicle, Ts, or DHT; 
and 3) WKYs matched those of VEGF, described above, using 
Western blot analysis (Fig. 4A) and ELISA (Fig. 4B), indi- 
cating a disruption of VEGF signaling. 
Expression of ERa, ER[3, and aromatase 
To determine whether the estrogen-ER system is disrupted 
in sham-operated SHRSPs, we investigated the expression 
patterns of ERa, ER[3, and aromatase, the enzyme that con- 
verts Ts to estrogen. 
ERa, ER[3. ER[3, the major subtype expressed in the fron- 
tocortical neurons, remained  unchanged in both sham- 
operated SHRSPs and WKYs, in all groups examined (see 
Figs. 1, 5B, and 7; and Table 2), whereas ERa expression 
showed a pronounced change, which was strikingly sim- 
ilar to that of VEGF described earlier, based on immuno- 
histochemical (Fig. 1), Western blot analysis (Fig. 5A), in 
situ hybridization (Fig. 7), and real-time PCR data (Table 
2). ER bands of predicted size (ERa, 65 kDa; ER[3, 55 kDa) 
were detected in the frontocortical tissues using NCL-ER- 
6F11 (ERa) and PA1–311 (ER[3) antisera (Fig. 5, A and B). 
The specificities of these antibodies in rat tissues have been 
well characterized in our previous report (55) by using 
controls, including omission of the primary antiserum, 
omission of the secondary antibody, and adsorption of the 
primary antiserum with its respective antigen. These pro- 
cedures were also repeated in the brain tissue in the 
present study (data not shown). 
 
Aromatase. The expression of cytochrome P450 aromatase 
protein (Figs. 1 and 6B) and mRNA (Fig. 7 and Table 2) 
matched that of ERa, described earlier. The down-regulated 
aromatase was attenuated by castration of SHRSPs and, sub- 
sequently, reverted to precastration levels by replacement 
with DHT but not Ts (Figs. 1, 6B, and 7; and Table 2). The 
predicted size of aromatase bands (~58 kDa) was detected 
in the frontal cortex (Fig. 6B). 
 
Expression of AR 
The increase in plasma levels of Ts and DHT in sham 
SHRSPs led us to examine the frontocortical pattern of their 
receptor, AR. Corresponding to the pattern of its ligands, Ts 
and DHT, AR expression levels in sham-operated SHRSPs 
were up-regulated but down-regulated after castration (Figs. 
1, 6A, and 7; and Table 2). Administration of both ligands to 
castrated SHRSPs significantly increased (P < 0.01) AR levels 
(Figs. 1, 6A, and 7; and Table 2). In contrast, E treatment in 
sham-operated SHRSPs significantly down-regulated  AR 
(P < 0.01) (Fig. 6A and Table 2), whereas flutamide treatment 
only slightly down-regulated AR expression (P < 0.05) (Fig. 
6A and Table 2). The predicted size of AR bands (~98 kDa) 
was detected in the frontal cortex (Fig. 6A). 
WKY 
Sham+vehicle Cast+vehicle Cast+Ts 
SHRSP  
Cast+DHT Sham+E Sham+flutamide 
1 0.74 1.10 1.20 0.77 1.05 1.11 
1 0.75 1.16 1.13 0.78 0.98 1.12 
1 0.78 1.13 1.21 0.80 0.97 1.14 
1 0.77 0.95 1.03 0.65 0.96 1.02 
1 0.61 1.20 1.50 0.71 1.15 1.19 
1 1.02 1.00 0.95 0.97 1.01 0.99 
1 1.35 0.85 1.32 1.36 0.94 1.20 















FIG. 4. A and B, Immunoblot analysis for pAkt (A) 
in the frontocortical tissues of genetic control WKYs 
(lane 1), sham-operated SHRSPs (sham+vehicle) 
(lane 2), castrated SHRSPs [vehicle treated 
(cast+vehicle) (lane 3); Ts replaced (cast+Ts) (lane 
4); DHT replaced (cast+DHT) (lane 5)], sham-oper- 
ated SHRSPs treated with E (sham+E) (lane 6), and 
sham-operated SHRSPs treated with flutamide 
(sham+flutamide) (lane 7). The panel of bands, just 
above the histogram, shows representative blots of 
the type of animal and/or treatment, as described 
above. The intensity of the bands were plotted as 
histograms, as shown below the panel (A). In each of 
the experiments, the band obtained with control 
WKYs is normalized as 1.0. Data are shown as 
means ± SD of five separate experiments. B, The 
level of Akt protein that is phosphorylated at serine 
residue 473 in frontocortical tissue extract (n = 8) 
was quantitatively determined by ELISA. Data are 
shown as means ± SD. For both immunoblot and 
ELISA, statistical analysis was done using one-way 
ANOVA followed by Scheffé’s multicomparison test. 
*, P < 0.001 vs. WKY; #, P < 0.001 vs. sham-operated 















Capillary density in the frontal cortex of sham-operated 
SHRSPs, as determined by GS4 lectin staining, was sig- 
nificantly lower (29%), compared with genetic control 
WKYs. However, this trend was reversed by castration of 
SHRSP rats, resulting in a remarkable increase in GS4 
lectin-stained capillaries in frontal cortex that was almost 
comparable with WKYs (Fig. 8) (capillary density: WKY, 
sham SHRSP, castrated SHRSP, 980 ± 120, 686 ± 100, 965 ± 
105/mm2). Fluorescent immunostaining for FVIII and 
CD34 (data not shown) yielded comparable results to GS4 
lectin. 
Discussion 
Our study used a new animal model for AD/HD, juvenile 
male SHRSPs, and began to investigate angiogenic (VEGF 
signaling machinery) and hormonal factors likely to underlie 
two common phenomenons, namely reduced rCBF and male 
preponderance, associated with AD/HD (5–11). Plasma lev- 
els of DHT and Ts in sham-operated SHRSPs increased about 
2-fold, compared with WKYs, the genetic control animal. In 
contrast, levels of VEGF signaling cascade [VEGF, VEGF 
receptors (KDR and Flt-1), pAkt, and eNOS], ERa, aro- 
matase, and capillary density were significantly down-reg- 
ulated in the frontal cortex of sham-operated SHRSPs, com- 
FIG. 5. A and B, Immunoblot analysis for ERa (A), 
and ER[3 (B) in the frontocortical tissues of genetic 
control WKYs (lane 1), sham-operated SHRSPs 
(sham+vehicle) (lane 2), castrated SHRSPs [vehicle 
treated (cast+vehicle) (lane 3); Ts replaced 
(cast+Ts) (lane 4); DHT replaced (cast+DHT) (lane 
5)], sham-operated SHRSPs treated with E 
(sham+E) (lane 6), and sham-operated SHRSPs 
treated with flutamide (sham+flutamide) (lane 7). 
The experiments were conducted by loading equal 
amounts of proteins in each lane. The panel of 
bands, just above the histogram, shows represen- 
tative blots of the type of animal and/or treatment, 
as described above. The intensity of the bands were 
plotted as histograms, as shown below each panel. 
In each of the experiments, the band obtained with 
control WKYs is normalized as 1.0. Data are shown 
as means ± SD of five separate experiments for ERa
and of six separate experiments for ER[3. Statistical 
analysis was done using one-way ANOVA followed 
by Scheffé’s multicomparison test for basal data 
obtained from densitometry from each experiment 
before normalization. *, P < 0.001 vs. WKY; #, P < 
0.001 vs. sham-operated SHRSP; §, P < 0.001 vs. 
castrated SHRSP (vehicle). 
pared with age-matched WKYs but counteracted by 
castration, exogenous estrogens, or AR antagonist flutamide. 
DHT, but not Ts, reversed the up-regulatory effects of cas- 
tration on the target molecules. Interestingly, levels of AR 
were up-regulated in sham and castrated SHRSPs treated 
with DHT but down-regulated by castration and E or flut- 
amide. Levels of ER[3 remained unchanged. These findings 
are novel and provide new and important insights that may 
lead to improved understanding of the pathogenesis of male 
preponderance and cerebral blood flow abnormalities asso- 
ciated with AD/HD. 
Even though volumetric abnormalities in rCBF are com- 
mon in AD/HD patients (5–11), no study to date has inves- 
tigated mechanism(s) or factors likely to underlie this phe- 
nomenon. The present study revealed marked reductions in 
levels of an important CNS angiogenic factor, VEGF, its key 
signaling machinery (VEGF, KDR, Flt-1, pAkt, eNOS) in the 
frontocortical region of sham-operated SHRSPs. The de- 
crease in levels of active or pAkt, a critical downstream 
molecule that mediates VEGF-induced angiogenesis and 
phosphorylates eNOS, indicates a compromise of VEGF sig- 

















FIG. 6. A and B, Immunoblot analysis for AR (A), and aro- 
matase (B) in the frontocortical tissues of genetic control 
WKYs (lane 1), sham-operated SHRSPs (sham+vehicle) 
(lane 2), castrated SHRSPs [vehicle treated (cast+vehicle) 
(lane 3); Ts replaced (cast+Ts) (lane 4); DHT replaced 
(cast+DHT) (lane 5)], sham-operated SHRSPs treated with 
E (sham+E) (lane 6), and sham-operated SHRSPs treated 
with flutamide (sham+flutamide) (lane 7). The panel of 
bands, just above the histogram, shows representative blots 
of the type of animal and/or treatment, as described above. 
The intensity of the bands were plotted as histograms, as 
shown below each panel. In each of the experiments, the band 
of control WKYs was normalized as 1.0. Statistical analysis 
was done for the basal data before normalization using one- 
way ANOVA followed by Scheffé’s multicomparison test. *, 
P < 0.001 vs. WKY; #, P < 0.001 vs. sham-operated SHRSP; 















can also be phosphorylated by other factors, other than 
VEGF, such as estrogen (60). Because cerebral microvessels 
account for a considerable portion of total resistance to ce- 
rebral blood flow, which is coupled to brain metabolism (61), 
we also investigated capillary density in the frontal cortex of 
sham-operated SHRSPs. A concomitant decrease in capillary 
density, as revealed by lectin staining, and previous func- 
tional data showing rCBF reduction in juvenile male SHRSPs 
(62), are consistent with these observations. Moreover, the 
molecular and morphological changes observed here are 
consistent with rCBF data in 6-wk-old male WKYs and SHR- 
SPs in parallel experiments conducted in our laboratory: 
rCBF in WKYs was 33.60 ± 11.09 (ml/min per 100 g tissue, 
n = 8) and 21.99 ± 7.50 (ml/min per 100 g tissue, n = 8) in 
SHRSPs. 
It is reasonable, based on literature, to state that alter- 
ations of VEGF concentration to the degree observed in the 
present study could prove fatal, particularly if they occur 
at a critical time during brain development (63, 64). Co- 
incidentally, in the rodents, the critical time when the 
VEGF-dependent neuronal metabolism peaks runs from 
postnatal d 5–9 until a time when the metabolic needs of 
the developing brain tissues are established (63– 65). Fol- 
lowing this establishment, VEGF production is known to 
decrease and blood flow normalized. This report is the first 
to reveal marked reductions in VEGF/Akt/eNOS signal- 
ing cascade in an animal model for AD/HD. The precise 
explanation for the marked reduction in VEGF and its 
signaling system reported here are not completely clear. 
However, because reduced rCBF and male preponderance 
both commonly occur in both SHSRP and AD/HD patients 
and because both estrogen and Ts promote VEGF produc- 
FIG. 7. In situ hybridization analysis showing gene expres- 
sion of VEGF, KDR, Flt-1, eNOS, ERa, ER[3, AR, and aro- 
matase in the coronal section of the frontal cortex from genetic 
control WKYs, sham-operated SHRSP (sham+vehicle), cas- 
trated, vehicle-treated SHRSPs (cast+vehicle), castrated 
SHRSP replaced with Ts (cast+Ts), and castrated SHRSPs 
replaced with DHT (cast+DHT). Nuclei of cerebral vessels 
(internal diameter < 100 µm) stained with hematoxylin ap- 
pear bluish violet and target mRNAs appear as black grains. 
Magnification, X400. 
tion in vivo and in vitro and VEGF promoter contains 
response elements for both hormones, changes in gonadal 
hormone synthesis or metabolism may likely influence 
VEGF synthesis and signaling. We know that Ts up-reg- 
ulates VEGF expression in tissues such as higher vocal 
center of songbird neostriatum (66) and ventral prostate of 
castrated rats (38) and estrogen stimulates VEGF synthesis 
in tissues such as the female reproductive organs (39). 
Indeed, deletion of Ts effects by castration diminished 
levels of VEGF expression in the frontal cortex of juvenile 
male Wistar rats (Jesmin, S., unpublished observation, 
2003). On the other hand, in sham-operated juvenile male 
SHRSPs, levels of VEGF and its associated molecules were 
significantly down-regulated but up-regulated by castra- 
tion and exogenous estrogen or AR antagonist flutamide. 
Most importantly, DHT, but not Ts, attenuated the en- 
hanced levels of VEGF and its angiogenic signaling cas- 
cade induced by castration. 
Collectively,  the  present  findings  appear  to  point  to 
DHT as a factor that is likely to trigger disruption of VEGF 
and its associated molecules. This conclusion is further 
supported by the fact that plasma levels of DHT in juvenile 
SHRSPs were significantly higher than those of WKYs, and 
expression of aromatase in frontal cortex was significantly 
lower than WKYs. Indeed, a recent report showing that 
DHT blocks E-induced VEGF production (67) and that 
interference with 5a-reduction of Ts attenuates androgen- 
induced male behaviors (68) are consistent with our con- 
clusion. Alternatively, however, two of the major metab- 
olites downstream of DHT, namely 3a-diol and 3[3-diol, 
could influence levels of angiogenic molecules  (69). 
Higher levels of 3a-diol, which functions as a weak an- 
drogen and is readily reconverted to DHT, are likely to 
favor similar outcomes as DHT outlined above because it 
is capable of inducing Ts-regulated aggression and acts on 
')-aminobutyric acid-A receptor (68 –70). 3[3-Diol, on the 
other hand, which can also be reconverted to DHT, has 
estrogenic activity with lower affinities for ER, i.e. 10- and 
FIG. 8. Evaluations of capillaries in the coronal sections of the frontal 
cortex from genetic control WKYs, sham-operated SHRSPs (vehicle), 
and castrated SHRSPs (vehicle). Photomicrographs show capillary 
endothelial cells immunostained with lectin. Arrow indicates capil- 
lary in the frontal cortex. Nuclei of the cells in the frontal cortex were 
stained with hematoxylin. Magnification, X100. 
30-fold lower for ER[3 and ERa, respectively, compared 
with that of estradiol (71–74). The estrogenic effects of 
3[3-diol, which under the present experimental conditions 
tend to attenuate the effects of DHT in SHRSPs, seem 
unlikely because of its poor affinity for ER (73). 
Knowledge of the role of androgen and estrogen systems 
in the development of male behavior has greatly expanded 
in the recent past. Whereas Ts plays a key role in the mas- 
culinization process of the male brain (31), estrogen ensures 
a timely shift from the predominantly estrogenic prenatal 
phase to a predominantly androgenic postnatal phase by 
up-regulating AR levels. Therefore, it is possible that alter- 
ations in receptor levels of either hormones or possibly in the 
ratio or rate of E/DHT conversion from Ts, as highlighted 
here, could compromise the E/androgen-regulated pro- 
cesses in brain development. This could include vascular 
function and, possibly, lead to a predisposition to AD/HD 
development. Moreover, alterations in E/androgen systems 
may, in part, help to explain etiology of male preponderance 
observed in SHRSPs. 
Estrogen is believed to play an important function in psy- 
chiatric disorders (75), and recent evidence by ER gene de- 
letion studies show that both ERa and -[3 are involved in the 
regulation of different types of male behaviors (76). In the 
present study, only levels of ERa, but not ER[3, decreased in 
the frontal cortex of sham-operated SHRSPs, an effect re- 
versed by E, flutamide, castration, or treatment of castrated 
SHRSPs with Ts. Furthermore, in addition to low ERa ex- 
pression, frontocortical aromatase and circulating E levels 
were also disrupted in sham-operated SHRSPs, compared 
with genetic control WKYs. Interestingly, when DHT was 
given to castrated SHRSPs, it down-regulated the elevated 
levels of ERa induced by castration. These findings are con- 
sistent with previous clinical data implicating ERa in the 
pathogenesis of cognitive diseases such as schizophrenia, a 
bipolar disorder, but most importantly, AD/HD (20). Col- 
lectively, the above data indicate that the inhibitory effects of 
DHT on ERa and aromatase expression might be mediated 
by AR. The present findings correlate with data of previous 
studies, which localized ERa in discrete areas of human brain 
related to cognition (77), and our most recent work, which 
revealed a 1:3 ratio of ERa and ER[3 levels in the frontal cortex 
of middle-aged female rat (53). Moreover, ER knockout 
(ERKO) mice studies have shown a marked reduction in 
frontal cortex-regulated male aggression behavior in ERaKO 
(78) but, on the contrary, a significant increase in ER[3KO 
mice (79). Furthermore, locomotion activity, which is dis- 
rupted in AD/HD (hyperactivity), is completely abolished in 
ERaKO but not in ER[3KO (80). It is worth noting that the 
molecular data of the present study matched those of the 
behavioral studies, submitted elsewhere. Arguably, it is too 
early at this point to link alterations of ERa levels to AD/HD. 
More work is required to elucidate the specific roles of ERa
and -[3 because levels of ER[3 in the cerebral cortex, hip- 
pocampus, and basal forebrain, critical sites for cognition 
function, are far greater than those of ERa. Additionally, 
more investigations are required to demonstrate the precise 
nature of the interaction between E and Ts in SHRSPs. 
In contrast to SHRSP, when WKYs were castrated, atten- 
tional performance tended to worsen, although this was not 
statistically significant. Castration of SHRSPs reversed the 
behavioral and attentional abnormalities in SHRSPs, a model 
of AD/HD (data submitted elsewhere). Moreover, whereas 
castration of SHRSPs up-regulated VEGF levels in the frontal 
cortex, it down-regulated levels of VEGF in WKYs by about 
15%. This should not be surprising because androgens are 
known to induce VEGF expression in a variety of tissues (38, 
66). These are the striking differences between the two rat 
strains in both attention performance and VEGF levels after 
castration, which prompted us launch detailed investiga- 
tions into the SHRSPs. 
The dosage of E used in the present treatments, although 
effective in improving behavioral abnormalities and fronto- 
cortical vascular factor expressions in SHRSP, is, admittedly, 
on the higher side. It is, therefore, essential that future studies 
determine the minimum dosage of E, which will restore 
normal attentional performance and the levels of frontocor- 
tical vascular factors in SHRSPs. 
In summary, we conclude that alterations in gonadal hor- 
mone metabolism during development of frontocortical neu- 
rons could alter VEGF angiogenic signaling cascade. This, in 
turn, may trigger volumetric abnormalities in cerebral blood 
flow of frontal cortex in SHRSPs and, consequently, com- 
promise the supply of essential nutrients and elements for 
optimal neuronal activity and brain function. Although the 
brain development time-line between rodent and man are 
remarkably consistent (81), it is obviously premature at this 
point to extrapolate the present data to humans. However, 
the present animal model and data do lay some foundation 
for future studies aimed at elucidating mechanisms likely to 
underlie volumetric abnormalities in frontal cerebral blood 
flow of AD/HD, an essential step in the effective manage- 
ment of AD/HD. 
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